More on the HQH closed-end biotech fund:
[ js_nh FYI: Here are the holdings of HQH as of 12/31/04 (the latest reporting date) based on the company’s SEC filing. In most cases, private-company investments are those listed as convertible securities (these are “preference” shares that convert into common shares upon an IPO) or as “restricted” common shares. On 12/31/04, the ten largest positions were AMGN, GENZ, CBST, TEVA, IXPL, CONR (since gone public), CHIR, NBIX, ENDP, and PRX.]
>>
Convertible securities: 12.7% of NAV
2,380,953 Agilix Corporation Series B $ 571,429
850,436 Avalon Pharmaceuticals Series B 1,020,523
375,000 Ceres, Inc. Series C 2,250,000
27,443 Ceres, Inc. Series C-1 164,658
277,967 Ceres, Inc. Series D 1,667,802
1,398,732 Galileo Pharmaceuticals, Inc. Series F-1 489,556
1,212,709 Idun Pharmaceuticals, Inc. Series A-1 2,486,053
462,963 Idun Pharmaceuticals, Inc. Series B-1740,741
1,750,000 Triad Therapeutics, Inc. Series A 1,750
525,000 Triad Therapeutics, Inc. Series B 525
1,200,000 Triad Therapeutics, Inc. Series C 24,000
300,000 Zyomyx, Inc. Series A New 30,000
300 Zyomyx, Inc. Series B New 30
952,381 Agensys, Inc. Series C 3,000,000
2,586,207 Corus Pharma, Inc. Series C 3,000,000
1,818,182 Raven biotechnologies Series B 1,509,091
2,809,157 Raven biotechnologies Series C 2,331,600
47,407 Therion Biologics Corporation Series A 85,333
240,000 Therion Biologics Corporation Series B 432,000
407,712 Therion Biologics Corporation Series C 733,882
36,092 Therion Biologics Corporation Sinking Fund 361
2,100,000 Xanthus Life Sciences, Inc. Series B 2,100,000
1,577,144 CardioNet, Inc. Series C 5,520,004
484,829 CytoLogix Corporation Series A 399,984
227,130 CytoLogix Corporation Series B 187,382
160,000 I-trax, Inc. Series A 3,184,000
5,384,615 PHT Corporation Series D 4,200,000
1,204,495 PHT Corporation Series E 939,506
4,852,940 Concentric Medical, Inc. Series B 4,173,527
1,744,186 Concentric Medical, Inc. Series C 1,500,000
222,222 EPR, Inc. Series A 2,222
160,000 Masimo Corporation Series D 1,760,000
1,632,653 OmniSonics Medical Technologies, Inc. Series B 2,181,224
1,547,988 OmniSonics Medical Technologies, Inc. Series C 1,800,000
652,173 TherOx Series H 247,826
CytoLogix Corporation 6.75% Cvt. Note 168,337
TherOx 6.0% Bridge Note, due 2006 200,272
TOTAL CONVERTIBLE SECURITIES
(Cost $68,450,111) $ 49,103,619
COMMON STOCKS: 77.0% of NAV
Biopharmaceuticals - 30.0% of NAV
263,891 Amgen, Inc. $ 16,928,608
153,900 Celgene Corporation 4,082,967
286,000 Chiron Corporation 9,532,380
1,021,657 Cubist Pharmaceuticals, Inc. 12,086,202
450,000 Endo Pharmaceuticals Holdings 9,459,000
207,000 Genzyme Corporation 12,020,490
214,000 Gilead Sciences, Inc. 7,487,860
138,000 Imclone Systems, Inc. 6,359,040
290,000 King Pharmaceuticals, Inc. 3,596,000
329,000 MedImmune, Inc. 8,919,190
180,000 Millennium Pharmaceuticals, Inc. 2,181,600
217,800 NPS Pharmaceuticals, Inc. 3,981,384
188,000 Neurocrine Biosciences, Inc. 9,268,400
224,400 Pfizer, Inc. 6,034,116
252,800 Pozen, Inc. 1,837,856
464,900 Vivus, Inc. 2,068,805
Drug Delivery - 3.3% of NAV
208,824 Connetics Corporation 5,072,335
750,533 DepoMed, Inc. 4,052,878
258,920 Penwest Pharmaceuticals Co. 3,096,683
66,000 Penwest Pharmaceuticals Co. (Restricted) 670,956
Drug Discovery Technologies - 3.5% of NAV
833,200 deCODE Genetics, Inc. 6,507,292
857,143 Senomyx, Inc. 7,097,144
300,000 Zyomyx, Inc. (Restricted) 3,000
Emerging Biopharmaceuticals - 17.3% of NAV
565,000 ACADIA Pharmaceuticals, Inc. 3,825,050
632,100 Adolor Corporation 6,270,432
633,041 Ariad Pharmaceuticals, Inc. 4,703,495
418,400 Cytokinetics, Inc. 4,288,600
221,100 DOV Pharmaceutical, Inc. 3,990,855
548,102 Dyax Corporation 3,957,296
732,600 Exelixis, Inc. 6,959,700
717,400 Guilford Pharmaceuticals, Inc. 3,551,130
568,600 Kosan Biosciences, Inc. 3,940,398
182,120 Momenta Pharmaceuticals, Inc. 1,285,767
510,880 Myogen, Inc. 4,122,802
102,176 Myogen, Inc., Warrants 27,588
417,750 Neurogen Corporation 3,910,140
139,200 Nuvelo, Inc. 1,371,120
506,292 Seattle Genetics, Inc. 3,306,087
200,609 Telik, Inc. 3,839,848
77,026 Tercica, Inc. 771,030
157,887 Theravance, Inc. 2,826,177
265,654 Theravance, Inc. (Restricted) 3,804,165
226,760 Therion Biologics Corporation (Restricted) 2,268
33,332 Therion Biologics Corporation (Restricted) C-2 Units 59,998
Generic Pharmaceuticals - 11.0% of NAV
164,700 Barr Pharmaceuticals, Inc. 7,500,438
623,067 Impax Laboratories, Inc. 9,894,304
308,250 IVAX Corporation 4,876,515
228,000 Par Pharmaceutical Companies, Inc. 9,434,640
355,200 Teva Pharmaceutical Industries, Ltd. ADR 10,606,272
Healthcare Services - 2.7% of NAV
26,125 DakoCytomation, Inc. (Restricted) 271,961
260,000 Provident Senior Living Trust (Restricted) 3,900,000
306,208 Syntiro Healthcare Services (Restricted) 3,062
754,500 WebMD Corporation 6,156,720
Medical Devices and Diagnostics - 9.0% of NAV
200,000 Boston Scientific Corporation 7,110,000
949,200 Conor Medsystems, Inc. (Restricted) 9,859,815
142,326 IDEXX Laboratories, Inc. 7,769,577
160,000 Masimo Corporation (Restricted)1,600
1,020,000 Orthovita, Inc. 4,273,800
208,529 Songbird Hearing, Inc. (Restricted) 2,085
546,875 VNUS Medical Technologies, Inc. (Restricted) 5,915,000
TOTAL COMMON STOCKS
(Cost $234,371,888) $ 296,733,921
SHORT-TERM INVESTMENTS - 11.2% of NAV
(Cost $43,192,908) $ 43,192,908
TOTAL INVESTMENTS
(Cost $346,014,907) $ 389,030,448
<<
AI
